CSF2 and hereditary clear cell renal cell carcinoma: Tani et al. (131) tested the clinical efficacy of GM-CSF-translated autologous renal tumor cell vaccine (GVAX) in four patients with stage IV renal cell carcinoma in Japan shown that GVAX greatly improved the immune antitumor and humoral responses of patients with renal cell carcinoma.